The medical board of the National Psoriasis Foundation has published treatment target guidelines for plaque psoriasis online in the Journal of the American Academy of Dermatology.1

An urgent need exists in the United States to establish treatment goals in psoriasis, according to the authors. With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.

Psychological therapies can improve both mental health and daily functioning in irritable bowel syndrome, with cognitive behavior therapy (CBT) producing the greatest improvements to daily functioning, according to a new study.

New York, NY Date – The Crohn’s & Colitis Foundation of America (CCFA) will be hosting IBD Clinical Trials Workshop: Principles and Practice on January 13-14, 2017 at the Renaissance Marriott Hotel in Nashville, Tennessee.

Psoriasis

Recent results from the VOYAGE 1 trial, the first of 3 pivotal phase 3 studies, demonstrated psoriasis patients who were administered guselkumab (Janssen Research and Development, LLC) achieved higher proportions of cleared to minimal psoriasis compared with patients receiving the placebo or adalimumab (Humira ).

Tags: 

(Reuters) An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday. 

The J&J drug, guselkumab, met the trial's primary goal, demonstrating statistically significant superior efficacy after 16 weeks of treatment and maintaining its advantage through week 48, the company said.

Pages